Avid Bioservices Inc (CDMO)

[jakedogman1]

follow the twitter trail

https://twitter.com/sloan_kettering

Preview what’s coming at #AACR17 from Parker Institute scientists @MDAndersonNews @sloan_kettering @PennCancer http://bit.ly/2nO56mX


http://www.parkerici.org/media/2017/parker-institute-for-cancer-immunotherapy-scientists-to-present-research-on?utm_content=buffere296a&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

Other adoptive cell therapy abstracts of interest:
• Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model
The principal investigator is Taha Merghoub, PhD, Parker Institute member researcher at Memorial Sloan Kettering Cancer Center. Co-authors include Parker Institute Center Director Jedd Wolchok, MD, PhD, at Memorial Sloan Kettering Cancer Center.